Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies

被引:12
作者
Lindboe, CF [1 ]
Von der Ohe, G
Torp, SH
机构
[1] Vest Agder Hosp, Dept Pathol, N-4604 Kristiansand S, Norway
[2] Norwegian Univ Sci & Technol, St Olavs Hosp, Dept Pathol, Dept Lab Med, N-7034 Trondheim, Norway
关键词
immunohistochemistry; proliferation index; Ki-67; MIB-1;
D O I
10.1034/j.1600-0463.2003.1110505.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Paraffin sections from 23 tumours were immunohistochemically stained with the following four Ki-67 equivalent antibodies: monoclonal MIB-1 (DAKO), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (DAKO). Ki-67 labelling indices were determined by counting in exactly the same area in each case. MIB-1 showed the highest labelling index in 21 of the 23 cases, and the mean MIB-1 index was approximately 30% higher than that of the other antibodies. The differences between MM1, NCL-Ki-67p and Rah Ki-67 were small and nonsignificant. There was a positive correlation between each of the four antibodies. As these findings may be of importance when the Ki-67 labelling index is used as a criterion for tumour grading or for clinical prognostication, this necessitate identification of the antibody used in every case.
引用
收藏
页码:567 / 570
页数:4
相关论文
共 13 条
[1]
Enestrom S, 1998, NEUROCHIRURGIE, V44, P25
[2]
MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up [J].
Geisler, JP ;
Geisler, HE ;
Miller, GA ;
Wiemann, MC ;
Zhou, Z ;
Crabtree, W .
GYNECOLOGIC ONCOLOGY, 1999, 75 (03) :432-436
[3]
Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas [J].
Hsu, DW ;
Louis, DN ;
Efird, JT ;
HedleyWhyte, ET .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (08) :857-865
[4]
MIB-1 labelling index is an independent prognostic marker in primary breast cancer [J].
Jansen, RLH ;
Hupperets, PSGJ ;
Arends, JW ;
Joosten-Achjanie, SR ;
Volovics, A ;
Schouten, HC ;
Hillen, HFP .
BRITISH JOURNAL OF CANCER, 1998, 78 (04) :460-465
[5]
MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: An immunohistochemical study including correlations with p53, bcl-2 and histological characteristics [J].
Jensen, V ;
Hoyer, M ;
Sorensen, FB ;
Keller, J ;
Jensen, OM .
HISTOPATHOLOGY, 1996, 28 (05) :437-444
[6]
PROLIFERATION MARKERS IN BREAST-CARCINOMA - MITOTIC FIGURE COUNT, S-PHASE FRACTION, PROLIFERATING CELL NUCLEAR ANTIGEN, KI-67 AND MIB-1 [J].
KESHGEGIAN, AA ;
CNAAN, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 104 (01) :42-49
[7]
Comparison of Ki-67 equivalent antibodies [J].
Lindboe, CF ;
Torp, SH .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (06) :467-471
[8]
Prayson R A, 2000, Ann Diagn Pathol, V4, P218, DOI 10.1053/adpa.2000.8124
[9]
Correlation between MIB-1 and other proliferation markers -: Clinical implications of the MIB-1 cutoff value [J].
Spyratos, F ;
Ferrero-Poüs, M ;
Trassard, M ;
Hacène, K ;
Phillips, E ;
Tubiana-Hulin, M ;
Le Doussal, V .
CANCER, 2002, 94 (08) :2151-2159
[10]
Torp SH, 2002, PATHOL RES PRACT, V198, P261